OncoMatch/Clinical Trials/NCT06504199
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Is NCT06504199 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for mantle cell lymphoma.
Treatment: Obinutuzumab · Zanubrutinib · Lenalidomide · Cytarabine · CAR-T — This study aims to preliminarily explore the efficacy and safety of the combination of Obinutuzumab and Zanubrutinib plus Lenalidomide (ZGR) followed by a short cycle of cytarabine and Obinutuzumab in the induction treatment of newly diagnosed mantle cell lymphoma (MCL) . The investigators propose ZGR followed by a short cycle of Obinutuzumab and cytarabine could be an effective first-line treatment for MCL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational drug
Previous use of investigational drugs
Lab requirements
Blood counts
ANC ≥ 1 × 10^9/L; Platelet count (PLT) ≥ 75 × 10^9/L (no blood transfusion, no use of hematopoietic factors and no use of drugs for correction within 14 days)
Kidney function
Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula)
Liver function
Total bilirubin (TBIL) ≤ 2.0 × ULN; ALT, AST ≤ 2.0 × ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Normal function of vital organs, i.e. meeting the following criteria: ... see above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify